Monthly information on share capital and company voting rights
Cellectis (CLLS) reported its monthly share capital and voting rights information for Euronext Growth.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellectis (CLLS) reported its monthly share capital and voting rights information for Euronext Growth.
As of May 31, 2026, the company had 100,691,658 shares outstanding and a total of 106,134,467 voting rights (ISIN: FR0010425595).
Details
News Market Reaction – CLLS
On Jun 4, the first trading day after this news, CLLS closed 1.94% above the previous close. That session’s volume was 2.7x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Jun 4 session.
Key Figures
- Total shares
- 100,691,658
- Total number of shares in the capital as of 05/31/2026
- Total voting rights
- 106,134,467
- Total number of voting rights as of 05/31/2026
- Reference date
- 05/31/2026
- Date of share capital and voting rights snapshot
Historical Context
-
Announcement of June 25, 2026 annual shareholders general meeting in Paris.
-
Plans to present new clinical data on lasme-cel and eti-cel at EHA 2026.
-
Release of first quarter 2026 financial results and operating update.
-
Monthly disclosure of April 30, 2026 share capital and voting rights table.
-
Notification of May 11, 2026 Q1 results release without a conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
isin code financial
voting rights regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARIS, June 03, 2026 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 05/31/2026 | 100,691,658 | 106,134,467 |
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachments
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.